InspireMD, Inc. announced that the company has entered into a strategic agreement with the Jacobs Institute at the State University of New York at Buffalo, and Dr. Adnan Siddiqui, Vice-Chairman and Professor of Neurosurgery, to execute an Early Feasibility Study (EFS) evaluating the CGuard EPS carotid stent to treat severe carotid stenosis or occlusion, in conjunction with thrombectomy, in patients presenting with acute ischemic stroke and tandem lesions. Examples of such statements include, but are not limited to, statements relating to the C-GUARDI's U.S. IDE clinical trial, including 30-day results from such trial, as well as the timing and outcome of any subsequent results, the EFS, PMA or potential launch.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2 USD | +4.44% | -4.31% | -28.83% |
Mar. 06 | Transcript : InspireMD, Inc., Q4 2023 Earnings Call, Mar 06, 2024 | |
Mar. 06 | Earnings Flash (NSPR) INSPIREMD Posts Q4 Revenue $1.8M | MT |
1st Jan change | Capi. | |
---|---|---|
-28.83% | 46.85M | |
-2.31% | 187B | |
-3.20% | 106B | |
-5.04% | 66.9B | |
+0.20% | 49.45B | |
+17.29% | 48B | |
+4.06% | 40.84B | |
+2.07% | 26.48B | |
+2.36% | 26.25B | |
+12.96% | 24.62B |
- Stock Market
- Equities
- NSPR Stock
- News InspireMD, Inc.
- InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions